Introduction
============

Guillain-Barré syndrome (GBS) is a rare and serious autoimmune disorder of peripheral nerves. A number of subtypes of GBS are recognized: acute inflammatory demyelinating polyradiculoneuropathy (the most common form marked by an areflexive muscular weakness evolving subacutely), Miller Fisher syndrome, acute motor axonal neuropathy, and acute motor-sensory axonal neuropathy.[@b1-imcrj-9-357],[@b2-imcrj-9-357] Fulminant cases of GBS have been reported in which a rapid clinical deterioration can mimic brain death. This clinical presentation is very rare, and disease diagnosis can be challenging.

Case presentation
=================

Mr. X, a 47-year-old Caucasian male patient with no medical history visited the emergency unit on July 17, 2007 because of diplopia and dysphonia that had appeared during the night. On admission, the Glasgow coma scale score was 15/15, hemodynamics were preserved, and body temperature was 37.4°C. Medical history showed that the patient had diarrhea that lasted for one week, without improvement even after 5 days of symptomatic treatment. There was no report of recent vaccinations or travel. Clinical examination showed diplopia and dysphonia with nasal speech. He did not present any muscular weakness or sensory loss, and osteotendinous reflexes were present and symmetrical. Cranial nerve examination did not show swallowing disorder, oculomotor disorder, or facial paralysis. The patient had no difficulty in walking, no pain or amyotrophy, no sphincter disorder, and no cauda equina syndrome. The plantar reflex was in flexion.

Laboratory tests were also normal. A brain CT with and without contrast was unremarkable. Lumbar puncture showed a clear cerebrospinal fluid with normal leukocyte count (less than 5/mm^3^ cells), proteins 44 mg/dL (normal range 20--40 mg/dL), glucose 61 mg/dL (n=45--80), and chloride 123 mEq/L (n=116--127). Cerebrospinal fluid culture remained negative after 2 days.

Yet, 3 hours after admission, became marked impairing speech, and paresthesia and numbness of the tongue was observed. Mr. X also reported paresthesia in his hands, without motor deficit. A Doppler ultrasound of carotid and vertebral arteries was unremarkable. While awaiting the results of bacteriological and viral testing, an empirical antibiotic treatment with amoxicillin, acyclovir, and sulfamethoxazole--trimethoprime was started in the eventuality of meningitis or meningoencephalitis.

A Guillain-Barré syndrome was suspected, and so the patient was transferred to the medical intensive care unit. On admission to the intensive care unit, the patient was conscious and had a Glasgow coma scale score of 15/15. There was persistent dysphonia and impaired swallowing and vision; otherwise, the neurological examination was unchanged. Invasive ventilation was initiated soon after.

Antibiotic therapy was switched to amoxicillin--clavulanic acid for one week in view of suspected aspiration pneumonia. Intravenous immunoglobulin (IVIG) therapy was started on admission at 0.4 g/kg a day for 5 days. Sedation (midazolam and remifentanil) was stopped on day 1; on day 3, the patient showed no sign of awakening. The Glasgow coma scale score was 3. The pupils were in nonreactive bilateral mydriasis.

Investigations and treatment
============================

A second lumbar puncture was performed on day 2; cerebrospinal fluid was clear with less than 5 cells/mm^3^ and showed slightly elevated protein level at 89 mg/dL and normal glucose at 74 mg/dL and chloride at 123 mEq/L. There were no microorganisms identified. A brain magnetic resonance imaging showed no evidence of ischemic lesion or tumor. On electromyogram, a segmental and focal demyelination with a complete conduction block was seen, but this did not explain the impairment of consciousness. Electroencephalogram trace was compatible with paradoxical sleep. The suspected diagnosis was fulminant GBS. Auditory evoked potentials were not contributory, giving evidence of a hearing loss to below 60 decibels. The diagnostic serology for *Campylobacter jejuni* (*C. jejuni*) was positive, with an antibody IgM isotype titer of 1:320 determined by ELISA (positivity threshold value at 1:20). Further investigations ruled out the presence of the following: botulinum toxins, *Campylobacter fetus*, listeriosis, HBV, HCV, HIV, EBV, HSV, CMV, syphilis, *Borrelia*.

A percutaneous tracheostomy was rapidly performed. Because of the lack of neurological improvement over several weeks, a second course of IVIG was given. At the end of the course, there was a slight clinical improvement as the patient could move the toes on both feet in response to simple commands. A third course of IVIG was given. Progress was marked by slight movements of the head and few movements of both eyelids. Mr. X benefited from four plasma exchanges and a fourth course of IVIG. With regard to muscular power, a strengthening of the upper and lower girdles was noted, with a result of 1/5 on motor testing. However, there was a persistent tetraplegia. With regard to sensitivity, a subjective improvement in the sensibility of the forearms and the back were noted. As Mr. X developed a severe reactional depressive syndrome, he was given an antidepressant treatment along with psychological treatment during his hospitalization. It should be noted that the patient had pain in the right hip for several weeks, a scan showed periarthritis of neurogenic origin. Breathing status improved slowly, enabling spontaneous breathing for a few hours per day at 3 months, with mechanical ventilation at night. The progress was marked by three episodes of ventilator-associated pneumonia.

Outcome and follow-up
=====================

The patient was transferred to a rehabilitation center 4 months after his initial admission to the hospital. Rehabilitation was slow despite daily physiotherapy combined with activities involving an occupational therapist and psychomotility therapist. After an essentially passive mobilization phase designed to maintain the trophicity and mobility of the joints, the patient was able to spend prolonged periods in a chair at 8 months and began to get about in a wheelchair at 9 months. Otherwise, full weaning from ventilation and final cannula removal took place at 10 months. Readaptation to orthostatism was progressive, and then rehabilitation in a swimming pool at 12 months facilitated active mobilization. At the same time, motor work and sensory and proprioceptive stimulation were essential. The patient was discharged home one year later with continuation of rehabilitation sessions for 2 years. After requiring the use of an electric wheelchair and then a manual one, he was able to stand up again after two years, in March 2009, and was able to walk by June 2009.

Currently, muscular weakness persists, grade 3--4/5, with regard to flexion and extension. On a functional level, Mr. X walks with 2 crutches with a forearm support and is still dependent in his day-to-day life, requiring assistance with washing and dressing, but he goes alone to the swimming baths, rides an electric tricycle outside, and drives an adapted automatic car with a special license. He no longer has dysphonia or slight difficulty swallowing. No significant improvement in muscular strength has been noted for the last 3 years.

Discussion
==========

Guillain-Barré syndrome in its fulminant form is very rare. The strength of our case is in the long-term follow-up, both in terms of quality of life and recovery long after the initial hospitalization, as 9 years have now passed since the acute phase. The patient is still severely disabled in spite of physiotherapy. His private, social, and professional life has been shattered. We believe this is the only paper detailing such a long-term follow-up of a fulminant GBS case.

Thirty-four cases have been previously described in the literature ([Table 1](#t1-imcrj-9-357){ref-type="table"}). Diagnosis can be very difficult when the patient is seen during the coma period with no previous case history. On day 3, our patient's Glasgow coma scale score was 3/15 and there was a nonreactive bilateral mydriasis. The presence of bilateral mydriasis has rarely been described in GBS.[@b3-imcrj-9-357] This finding can be explained by a demyelination of the synaptic and parasympathetic preganglionic fibers that supply the pupil.[@b4-imcrj-9-357] However, pupillary involvement is common in Miller Fischer syndrome, a variant of GBS, and mydriasis has also been reported in more than a third of Miller Fischer syndrome patients.[@b5-imcrj-9-357] Polyneuropathy is sometimes absent from the initial clinical picture.[@b4-imcrj-9-357] The outcome of lumbar puncture and the investigations are therefore all-important in this case.[@b6-imcrj-9-357],[@b7-imcrj-9-357] In some patients, a pathological analysis with nerve biopsy has been performed.[@b3-imcrj-9-357],[@b8-imcrj-9-357]--[@b10-imcrj-9-357] One common characteristic of the various reported cases is the rapid onset of "pseudo-coma," occuring on average 3 days from first symptoms. Electrophysiological studies have shown 18 cases with demyelination and 11 cases with axonal involvement ([Table 2](#t2-imcrj-9-357){ref-type="table"}).

Moreover, three cases of fulminant GBS with antecedent *C. jejuni* infection have been reported.[@b10-imcrj-9-357]--[@b12-imcrj-9-357] *C. jejuni* is the pathogenic agent most commonly found in cases of GBS preceded by diarrhea. Since the first cases described in 1982, the severity of GBS following infection with *C. jejuni* has been evidenced and includes frequent axonal involvement, slower recovery, and more severe disability.[@b13-imcrj-9-357],[@b14-imcrj-9-357]

Reported treatments were not homogeneous, and it is therefore impossible to establish a consensus. They are described in [Table 3](#t3-imcrj-9-357){ref-type="table"} but are not mentioned in every study. However, it is important to emphasize that repeated courses of IVIG may be effective in severe, unresponsive GBS.[@b15-imcrj-9-357] Our patient received four courses of IVIG and four plasma exchanges.

Publications including long-term data after fulminant GBS are very sparse in the literature, and so it is difficult to reach a conclusion on this point. However, recovery of neurological function in fulminant GBS seems to be poor, and the disease has a high mortality rate. Outcomes for patients affected with fulminant GBS are described in [Table 3](#t3-imcrj-9-357){ref-type="table"}. Absence of excitability on EMG and dependency on mechanical ventilation for more than one month are factors indicative of poor prognosis.[@b16-imcrj-9-357] Fulminant GBS has a more serious prognosis than "standard" GBS.[@b17-imcrj-9-357] Indeed, our literature review found 5/34 deaths (14.7%) and 52% severely disabled patients, as opposed to the lower reported rates of death and disability in "standard" GBS (4% and 14% respectively).[@b18-imcrj-9-357] It is worth noting that the majority of deaths in the cohort took place before 2000, (4/5) with dysautonomic complications being more frequent during this period. After the acute phase, GBS patients have both physical and cognitive disabilities that are amenable to improvement with rehabilitation programs focusing on specific complications (ie, therapeutic exercises avoiding overexertion for weakness, soaking techniques for sensory loss, transcutaneous electrical nerve stimulation for residual pain, biofeedback techniques for neurologic bladder and bowel).[@b19-imcrj-9-357] Moreover, rehabilitation of highly dependent GBS patients results in significant reduction in ongoing care costs and is cost-efficient despite significant residual disability.[@b20-imcrj-9-357]

When electrophysiological investigations are available, fulminant GBS is more likely to be accompanied by axonal damage (50% in our cohort), a feature associated with slower and less satisfactory functional recovery.[@b11-imcrj-9-357],[@b17-imcrj-9-357] Clinical cases for which a sural biopsy was carried out showed that axonal damage was preceded by a phase of severe distal demyelination with conduction blocks.[@b21-imcrj-9-357] Electroencephalogram (EEG) tracings typically identify alpha rhythm activity unresponsive to painful and auditory stimulation during fulminant GBS, but other tracings have also been reported (sleep, responsive or the so-called "alpha-delta" stage of sleep).[@b4-imcrj-9-357] Continuous EEG monitoring could be of particular interest in this setting to assess variability in EEG pattern over hours or days as opposed to minutes. Unfortunately, this procedure was not yet available in our institution.

The patient has recovered his cognitive functions but has no memory of the acute phase, as is commonly described in previously published cases.[@b22-imcrj-9-357] GBS can also be complicated by a reactive depressive syndrome.[@b2-imcrj-9-357],[@b23-imcrj-9-357] Our patient developed a depressive state, thus requiring specialist management with long-term antidepressant treatment.

Conclusion
==========

Fulminant GBS with brain-death presentation is rare but deserves medical knowledge and awareness. Its diagnosis leads to a well-established treatment that reduces long-term disability. This case reminds us of the importance of electrophysiological investigations during clinical brain-death states with no definite cause. Finally, long-term physiotherapy and specific rehabilitation programs appear essential to improve recovery.
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###### 

Clinical characteristics

  Study                                           Age/Sex      Patterns of deficit                                          History                           Pathogen          Time to nadir (days)
  ----------------------------------------------- ------------ ------------------------------------------------------------ --------------------------------- ----------------- ----------------------
  Carroll and Mastaglia,[@b24-imcrj-9-357] 1979   45/M         Generalized tetraparesis                                     Rhinopharyngitis                                    5
  Kotsoris et al,[@b25-imcrj-9-357] 1984          44/M         Generalized ascending tetraparesis                           NR                                                  2
  Al-din et al,[@b26-imcrj-9-357] 1985            45/M         NR                                                           NR                                                  3
  Drury et al,[@b6-imcrj-9-357] 1987              63/M         Generalized tetraparesis                                     Rhinopharyngitis                                    2
  Kanda et al,[@b9-imcrj-9-357] 1989              47/M         Generalized ascending tetraparesis                           Rhinopharyngitis                                    6
  Coad and Byrne,[@b27-imcrj-9-357] 1990          43/M         Diplopia followed by generalized tetraparesis                Rhinopharyngitis                                    4
  Hassan and Mumford,[@b28-imcrj-9-357] 1991      45/M         Muscle weakness, diplopia                                    Diarrhea                                            3
  Fuller et al,[@b3-imcrj-9-357] 1992             63/M         Generalized tetraparesis                                     NR                                                  2
  Marti-Masso et al,[@b22-imcrj-9-357] 1993       58/F         Dysphonia followed by generalized tetraparesis               NR                                                  2
  Tan and Chee,[@b7-imcrj-9-357] 1995             50/F         Muscle weakness followed by generalized tetraparesis         Diarrhea                                            2
  Bakshi et al,[@b8-imcrj-9-357] 1997             6/M          Generalized tetraparesis                                     Diarrhea                                            2
  Berciano et al,[@b10-imcrj-9-357] 1997          67/M         Dyspnea followed by generalized tetraparesis                 Diarrhea                          *C. jejunii*      2
  Bohlega et al,[@b17-imcrj-9-357] 1997           45/M         Generalized ascending tetraparesis                           NR                                                  3
  Hughes and McGuire,[@b29-imcrj-9-357] 1997      27/M         Difficulty swallowing followed by generalized tetraparesis   Rhinopharyngitis                                    5
  Thomas,[@b30-imcrj-9-357] 2000                  36/M         Generalized ascending tetraparesis                           Rhinopharyngitis                                    2
  Vargas et al,[@b4-imcrj-9-357] 2000             45/F         Generalized tetraparesis                                     Rhinopharyngitis                                    1
  Ragazzoni et al,[@b31-imcrj-9-357] 2000         40/M         Generalized ascending tetraparesis                           Rhinopharyngitis                                    2
  Stojkovic et al,[@b32-imcrj-9-357] 2001                      Generalized tetraparesis                                     Cranial trauma                                      2
  Saito,[@b12-imcrj-9-357] 2002                   21/M         Dysarthria                                                   Diarrhea                          *C. jejunii*      4
  Friedman et al,[@b11-imcrj-9-357] 2003          57/F         Distal paresthesias in lower limbs                           NR                                                  6
  Friedman et al,[@b11-imcrj-9-357] 2003          27/M         Diplopia, difficulty swallowing then tetraparesis            Cranial trauma                    *C. jejunii*      3
  Moussouttas et al,[@b33-imcrj-9-357] 2004       47/F         Distal paresthesias in lower limbs                           Cranial trauma                                      5
  Kang and Kim,[@b21-imcrj-9-357] 2007            32/M         Distal paresthesias in lower limbs, facial diplegia          Diarrhea                          Hepatitis A       4
  Tagami et al,[@b34-imcrj-9-357] 2008            65/M         NR                                                           NR                                *H. influenzae*   NR
  Rivas et al,[@b35-imcrj-9-357] 2008             55/M         Generalized tetraparesis                                     Cranial trauma                                      7
  Joshi et al,[@b36-imcrj-9-357] 2008             34/M         Generalized tetraparesis                                     NR                                                  2
  Joshi et al,[@b36-imcrj-9-357] 2008             59/M         Generalized ascending tetraparesis                           NR                                                  10
  Rigamonti et al,[@b37-imcrj-9-357] 2009         61/F         Muscle weakness followed by tetraparesis                     Diarrhea                                            1
  Tan et al,[@b38-imcrj-9-357] 2010               44/M         Distal paresthesias in lower limbs                           Cranial trauma                                      2
  Bernard et al,[@b39-imcrj-9-357] 2010           73/F         NR                                                           NR                                                  NR
  Sevketoglu et al,[@b40-imcrj-9-357] 2010        5/M          Dysphonia, difficulty swallowing                             NR                                                  1
  Medici et al,[@b41-imcrj-9-357] 2011            5/M          Dysarthria, facial diplegia                                  NR                                                  1
  Medici et al,[@b41-imcrj-9-357] 2011            3 months/M   Facial diplegia                                              Tetanus--diphtheria vaccination                     1
  Medici et al,[@b41-imcrj-9-357] 2011            8/M          Diplopia, dysarthria, tetraparesis                           Diarrhea                                            1

**Abbreviation:** NR, not reported.

###### 

Paraclinical characteristics

  Study                                           Lumbar puncture   Protein concentration (mg/dL)   NCS                              EEG                                     Biopsy
  ----------------------------------------------- ----------------- ------------------------------- -------------------------------- --------------------------------------- --------------------------------------------
  Carroll and Mastaglia,[@b24-imcrj-9-357] 1979   Dissociation      42                                                               Alpha                                   
  Kotsoris et al,[@b25-imcrj-9-357] 1984          Dissociation      462                             Inexcitability                   Alpha                                   
  Drury et al,[@b6-imcrj-9-357] 1987              Dissociation      58                              Inexcitability                   Alpha reactive                          
  Kanda et al,[@b9-imcrj-9-357] 1989              Dissociation      58                                                                                                       Demyelination
  Coad and Byrne,[@b27-imcrj-9-357] 1990          Dissociation      200                             Inexcitability                   Alpha                                   
  Hassan and Mumford,[@b28-imcrj-9-357] 1991      Normal            25                              Inexcitability                   Alpha reactive                          
  Fuller et al,[@b3-imcrj-9-357] 1992             Dissociation      75                              Inexcitability                   Alpha waves and diffuse beta activity   Primary demyelination, axonal degeneration
  Marti-Masso et al,[@b22-imcrj-9-357] 1993       Dissociation      75                              Axonopathy                       Alpha nonreactive                       
  Tan and Chee,[@b7-imcrj-9-357] 1995             Normal            20                              Inexcitability                   Alpha reactive                          
  Bakshi et al,[@b8-imcrj-9-357] 1997             Dissociation      167                             Inexcitability                   Reactive theta activity, sleep          Demyelination
  Berciano et al,[@b10-imcrj-9-357] 1997          Pleocytosis       198                             Inexcitability                   Alpha reactive                          Primary demyelination, axonal degeneration
  Bohlega et al,[@b17-imcrj-9-357] 1997           Dissociation      605                             Inexcitability                                                           Primary demyelination, axonal degeneration
  Hughes and McGuire,[@b29-imcrj-9-357] 1997      Dissociation      58                              Demyelination with axonal loss   Sleep                                   Primary demyelination, axonal degeneration
  Vargas et al,[@b4-imcrj-9-357] 2000             Dissociation      90                              Inexcitability                   Alpha                                   Primary demyelination, axonal degeneration
  Ragazzoni et al,[@b31-imcrj-9-357] 2000         Dissociation      70                              Inexcitability                   Reactive                                
  Stojkovic et al,[@b32-imcrj-9-357] 2001                           197                             Demyelination                                                            
  Saito,[@b12-imcrj-9-357] 2002                                     65                              Axonopathy                                                               
  Friedman et al,[@b11-imcrj-9-357] 2003          Dissociation                                      Inexcitability                   Theta                                   Axonal degeneration
  Friedman et al,[@b11-imcrj-9-357] 2003          Dissociation      58                              Axonopathy                       Alpha reactive                          
  Moussouttas et al,[@b33-imcrj-9-357] 2004       Dissociation                                      Inexcitability                   Nonspecific slowing                     
  Kang and Kim,[@b21-imcrj-9-357] 2007            Dissociation      115                             Axonopathy                       Alpha                                   
  Rivas et al,[@b35-imcrj-9-357] 2008             Dissociation                                      Inexcitability                   Alpha                                   Axonal degeneration
  Joshi et al,[@b36-imcrj-9-357] 2008             Dissociation                                      Inexcitability                   Nonspecific slowing reactive            
  Joshi et al,[@b36-imcrj-9-357] 2008                                                               Inexcitability                   Nonspecific slowing reactive            
  Rigamonti et al,[@b37-imcrj-9-357] 2009         Dissociation      85                              Inexcitability                   Nonspecific slowing                     
  Tan et al,[@b38-imcrj-9-357] 2010               Dissociation      182                                                                                                      Macrophages
  Bernard et al,[@b39-imcrj-9-357] 2010           Dissociation                                      Axonopathy                       Nonspecific slowing reactive            
  Sevketoglu et al,[@b40-imcrj-9-357] 2010        Dissociation      70                              Axonopathy                                                               
  Medici et al,[@b41-imcrj-9-357] 2011            Dissociation      117                             Axonopathy                                                               
  Medici et al,[@b41-imcrj-9-357] 2011            Dissociation      260                             Axonopathy                                                               
  Medici et al,[@b41-imcrj-9-357] 2011            Dissociation      180                             Axonopathy                                                               

**Abbreviations:** NCS, nerve conduction study; EEG, electroencephalogram.

###### 

Treatments and outcomes

  Study                                           Treatment                           Dysautonomia              "Brain death" (days)   Mortality              Other        Outcome
  ----------------------------------------------- ----------------------------------- ------------------------- ---------------------- ---------------------- ------------ ----------------------------------------------------------
  Carroll and Mastaglia,[@b24-imcrj-9-357] 1979                                                                                                               Amnesia      Walks with assistance (crutches)
  Kotsoris et al,[@b25-imcrj-9-357] 1984                                                                        6                                                          Handicapped, partial motor recovery
  Al-din et al,[@b26-imcrj-9-357] 1985                                                                          5                                                          Severe weakness (after 3 months)
  Drury et al,[@b6-imcrj-9-357] 1987                                                                            46                                            Amnesia      
  Kanda et al,[@b9-imcrj-9-357] 1989              PE                                  CA                        7 (death)              CA day 5                            
  Coad and Byrne,[@b27-imcrj-9-357] 1990                                                                        5                                                          Complete gradual recovery
  Hassan and Mumford,[@b28-imcrj-9-357] 1991                                                                                                                               6 months of mechanical ventilation, wheelchair
  Fuller et al,[@b3-imcrj-9-357] 1992             PE/corticosteroids                  Arrythmia, CA             7                      CA day 28                           
  Marti-Masso et al,[@b22-imcrj-9-357] 1993       PE(6)                               Arrythmia                 13                                            Amnesia      Can walk unaided after 1 year
  Tan and Chee,[@b7-imcrj-9-357] 1995             Gamma globulin                                                12                     Day 98                 Amnesia      Significant sequelae after 2 months
  Bakshi et al,[@b8-imcrj-9-357] 1997             Gamma globulin                                                "Few weeks"                                                Significant sequelae, walks with assistance after 1 year
  Berciano et al,[@b10-imcrj-9-357] 1997          PE/corticosteroids                  CA                                               CA day 18                           
  Bohlega et al,[@b17-imcrj-9-357] 1997           PE/gamma globulin                                             31                                                         Severe handicap, proximal recovery after 30 months
  Hughes and McGuire,[@b29-imcrj-9-357] 1997      Gamma globulin                                                                                                           Significant sequelae after 6 months
  Vargas et al,[@b4-imcrj-9-357] 2000             PE                                                                                                                       Severe handicap
  Ragazzoni et al,[@b31-imcrj-9-357] 2000         PE                                                                                                          Amnesia      
  Stojkovic et al,[@b32-imcrj-9-357] 2001         Gamma globulin                                                                                                           
  Saito,[@b12-imcrj-9-357] 2002                   PE/Gamma globulin(2)                Tachycardia                                                                          Significant sequelae predominantly in lower limbs
  Friedman et al,[@b11-imcrj-9-357] 2003                                                                        16                                                         4/5 Motor sequelae in upper limbs, 3/5 in lower limbs
  Friedman et al,[@b11-imcrj-9-357] 2003          Gamma globulin                                                                                              Amnesia      Partial proximal recovery, 3/5 in lower limbs
  Moussouttas et al,[@b33-imcrj-9-357] 2004       PE/gamma globulin                                                                                                        Complete recovery
  Kang and Kim,[@b21-imcrj-9-357] 2007            Gamma globulin/corticosteroids      Bradycardia                                                                          Good recovery and ability to walk
  Tagami et al,[@b34-imcrj-9-357] 2008            PE/gamma globulin                                                                                           Depression   Major sequelae
  Rivas et al,[@b35-imcrj-9-357] 2008                                                                                                                                      Handicapped
  Joshi et al,[@b36-imcrj-9-357] 2008                                                                                                                                      Handicapped
  Joshi et al,[@b36-imcrj-9-357] 2008                                                                                                                                      Handicapped
  Rigamonti et al,[@b37-imcrj-9-357] 2009         Gamma globulin                      Tachycardia               15                                                         Walks with assistance (crutches)
  Tan et al,[@b38-imcrj-9-357] 2010               Gamma globulin(2)                   Blood pressure lability                                                              
  Bernard et al,[@b39-imcrj-9-357] 2010           Gamma globulin                                                12                     Septic shock day 158                
  Sevketoglu et al,[@b40-imcrj-9-357] 2010        PE/gamma globulin(2)                                                                                                     Partial motor recovery
  Medici et al,[@b41-imcrj-9-357] 2011            PE/gamma globulin/corticosteroids                             7                                                          Complete recovery
  Medici et al,[@b41-imcrj-9-357] 2011            Gamma globulin                                                15                                                         Handicapped, partial recovery
  Medici et al,[@b41-imcrj-9-357] 2011            Gamma globulin                                                5                                                          

**Abbreviations:** PE, plasma exchange; CA, cardiac arrest.
